Immunization in Hematopoietic Cell Transplantation

References

• Advisory Committee on Immunization Practices Recommendations. Use of vaccines and immune globulins for persons with altered immunocompetence. MMWR 1993; 42: 1–18
   Google Scholar
• Pirofski L A, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 1998; 11: 1–26
   PubMed Web of Science ®Google Scholar
• Decker M D, Edwards K M, Steinhoff M C, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96: 557–566
   PubMed Web of Science ®Google Scholar
• Edwards K M, Meade B D, Decker M D, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response [see comments]. Pediatrics 1995; 96: 548–557
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Acellular pertussis vaccine: recommendations for use as the initial series in infants and children. Pediatrics 1997; 99: 282–288
   Google Scholar
• Vance E, George S, Guinan E C, et al. Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant 1998; 22: 735–741
   PubMedGoogle Scholar
• Ljungman P, Wiklund-Hammarsten M, Duraj V, et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990; 162: 496–500
   PubMed Web of Science ®Google Scholar
• Engelhard D, Handsher R, Naparstek E, et al. Immune response to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8: 295–300
   PubMedGoogle Scholar
• King S M, Saunders E F, Petric M, Gold R. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 633–636
   PubMed Web of Science ®Google Scholar
• Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159: 610–615
   PubMed Web of Science ®Google Scholar
• Torigoe S, Hirai S, Oitani K, et al. Application of live attenuated measles and mumps vaccines in children with acute leukemia. Biken J 1981; 24: 147–151
   PubMedGoogle Scholar
• Apalsch A M, Green M, Ledesma-Medina J, Nour B, Wald E R. Parainfluenza and influenza virus infections in pediatric organ transplant recipients. Clin Infect Dis 1995; 20: 394–399
   PubMedGoogle Scholar
• Whimbey E, Champlin R E, Couch R B, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996; 22: 778–782
   PubMed Web of Science ®Google Scholar
• Blumberg E A, Fitzpatrick J, Stutman P C, Hayden F G, Brozena S C. Safety of influenza vaccine in heart transplant recipients. J Heart Lung Transplant 1998; 17: 1075–1080
   Google Scholar
• Blumberg E A, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22: 295–302
   PubMed Web of Science ®Google Scholar
• Furth S L, Neu A M, McColley S A, Case B, Steinhoff M, Fivush B. Immune response to influenza vaccination in children with renal disease. Pediatr Nephrol 1995; 9: 566–568
   PubMed Web of Science ®Google Scholar
• Mauch T J, Bratton S, Myers T, Krane E, Gentry S R, Kashtan C E. Influenza B virus infection in pediatric solid organ transplant recipients. Pediatrics 1994; 94: 225–229
   PubMed Web of Science ®Google Scholar
• Admon D, Engelhard D, Strauss N, Goldman N, Zakay-Rones Z. Antibody response to influenza immunization in patients after heart transplantation. Vaccine 1997; 15: 1518–1522
   PubMed Web of Science ®Google Scholar
• ACIP issues recommendations on the prevention of varicella. Am Fam Physician 1996; 54: 2578–2581
   Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the use of live attenuated varicella vaccine. Pediatrics 1995; 95: 791–796, [published erratum appears in Pediatrics 1995 July;96(1 Pt 1): preceding 151 and following 171] [see comments]
   Google Scholar
• Guinan E C, Molrine D C, Antin J H, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994; 57: 677–684
   PubMed Web of Science ®Google Scholar
• Barra A, Cordonnier C, Preziosi M P, et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 1992; 166: 1021–1028
   PubMed Web of Science ®Google Scholar
• Molrine D C, Guinan E C, Antin J H, et al. Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Bone Marrow Transplant 1996; 17: 1149–1155
   PubMed Web of Science ®Google Scholar
• Molrine D C, Guinan E C, Antin J H, et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood 1996; 87: 3012–3018
   PubMed Web of Science ®Google Scholar
• Surveillance for diabetes mellitus–-United States, 1980–1989, and laboratory-based surveillance for meningococcal disease in selected areas–-United States, 1989–1991. MMWR 1993; 42: 21–30
   PubMedGoogle Scholar
• Peltola H, Kayhty H, Kuronen T, Haque N, Sarna S, Makela P H. Meningococcus group A vaccine in children three months to five years of age. Adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide. J Pediatr 1978; 92: 818–822
   PubMed Web of Science ®Google Scholar
• Gold R, Lepow M L, Goldschneider I, Draper T F, Gotshlich E C. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 1979; 140: 690–697
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices Recommendations. Control and prevention of meningococcal disease. MMWR 1997; 46: 1–10
   Google Scholar
• Quinti I, Velardi A, Le Moli S, et al. Antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. J Clin Immunol 1990; 10: 160–166
   Google Scholar
• Ambrosino D M, Molrine D C. Critical appraisal of immunization strategies for prevention of infection in the compromised host. Hematol Oncol Clin North Am 1993; 7: 1027–1050
   PubMedGoogle Scholar
• Musher D M, Luchi M J, Watson D A, Hamilton R, Baughn R E. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of absorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis 1990; 161: 728–735
   PubMed Web of Science ®Google Scholar
• Koskela M, Leinonen M, Haiva V M, Timonen M, Makela P H. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 1986; 5: 45–50
   PubMedGoogle Scholar
• Leinonen M, Sakkinen A, Kalliokoski R, Luotonen J, Timonen M, Makela P H. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis 1986; 5: 39–44
   PubMedGoogle Scholar
• Winston D J, Ho W G, Schiffman G, Champlin R E, Feig S A, Gale R P. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med 1983; 143: 1735–1737
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices Recommendations. Prevention of pneumococcal disease. MMWR 1997; 46: 1–24
   Google Scholar
• Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal Vaccine (Wyeth-Lederle) in 37,000 infants and children: Results of the Northern California Kaiser Pemanente Efficacy Trial. Abstracts of the 38th ICAAC. American Society for Microbiology, San Diego, CA 1998
   Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Prevention of hepatitis A infections: guidelines for use of hepatitis A vaccine and immune globulin. Pediatrics 1996; 98: 1207–1215
   Google Scholar
• Clemens R, Safary A, Hepburn A, Roche C, Stanbury W J, Andre F E. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171(Suppl 1)S44–49
   Web of Science ®Google Scholar
• McMahon B J, Williams J, Bulkow L, et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. J Infect Dis 1995; 171: 676–679
   PubMedGoogle Scholar
• Balcarek K B, Bagley M R, Pass R F, Schiff E R, Krause D S. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995; 171(Suppl 1)S70–72
   Google Scholar
• Horng Y C, Chang M H, Lee C Y, Safary A, Andre F E, Chen D S. Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J 1993; 12: 359–362
   Google Scholar
• Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants [Abstract H61]. Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, San Diego, CA 1995; 190
   Google Scholar
• Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children [see comments]. N Engl J Med 1992; 327: 453–457
   PubMed Web of Science ®Google Scholar
• Innis B L, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine [see comments]. JAMA 1994; 271: 1328–1334
   PubMed Web of Science ®Google Scholar
• Keeffe E B, Iwarson S, McMahon B J, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease [see comments]. Hepatology 1998; 27: 881–886
   PubMedGoogle Scholar
• Bodsworth N J, Neilsen G A, Donovan B. The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up. Aids 1997; 11: 747–749
   PubMed Web of Science ®Google Scholar
• Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. Immunization of adolescents. MMWR 1996; 45: 1–16
   Google Scholar
• Halsey N A. Discussion of Immunization Practices Advisory Committee/American Academy of Pediatrics recommendations for universal infant hepatitis B vaccination. Pediatr Infect Dis J 1993; 12: 446–449
   Google Scholar
• Advisory Committee on Immunization Practices Recommendations. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 1991; 40: 1–25
   Google Scholar
• Andre F E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989; 87: 14S–20S
   PubMed Web of Science ®Google Scholar
• Szmuness W, Stevens C E, Harley E J, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833–841
   PubMed Web of Science ®Google Scholar
• Zajac B A, West D J, McAleer W J, Scolnick E M. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986; 13(Suppl A)39–45
   PubMed Web of Science ®Google Scholar
• Stevens C E, Taylor P E, Tong M J, et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987; 257: 2612–2616
   PubMed Web of Science ®Google Scholar
• Hilleman M R. Yeast recombinant hepatitis B vaccine. Infection 1987; 15: 3–7
   Google Scholar
• Hepatitis B. Book: Report of the Committee on Infectious Diseases, G Peter. American Academy of Pediatrics, Elk Grove Village, IL 1997; Vol. 24: 253, 1997 Red.
   Google Scholar
• Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, Strauss N, Parag G, Naparstek E, Ravid Z, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993; 11: 1–5
   PubMed Web of Science ®Google Scholar
• Wimperis J Z, Brenner M K, Prentice H G, Reittie J E, Karayiannis P, Griffiths P D, Hoffbrand A V. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986; 15: 339–343
   Google Scholar
• O'Hagan D T. Recent advances in vaccine adjuvants for systemic and mucosal administration. J Pharm Pharmacol 1998; 50: 1–10
   PubMed Web of Science ®Google Scholar
• Liu M A. Vaccine developments. Nat Med 1998; 4: 515–519
   PubMed Web of Science ®Google Scholar
• Belshe R B, Mendelman P M, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children [see comments]. N Engl J Med 1998; 338: 1405–1412
   PubMed Web of Science ®Google Scholar
• Karron R A, Wright P F, Crowe J E, Jr., et al. Evaluation of two live, cold-passaged. temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997; 176: 1428–1436
   Google Scholar
• Piedra P A, Grace S, Jewell A, et al. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J 1998; 17: 217–224
   PubMed Web of Science ®Google Scholar
• Rodriguez W J, Gruber W C, Groothuis J R, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 1997; 100: 937–942
   PubMed Web of Science ®Google Scholar
• Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group [see comments]. Pediatrics 1997; 99: 93–99
   PubMed Web of Science ®Google Scholar
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group [see comments]. Pediatrics 1998; 102: 531–537
   PubMed Web of Science ®Google Scholar
• Plotkin S A, Higgins R, Kurtz J B, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994; 58: 1176–1178
   PubMed Web of Science ®Google Scholar
• Adler S P, Hempfling S H, Starr S E, Plotkin S A, Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 1998; 17: 200–206
   PubMed Web of Science ®Google Scholar